United Therapeutics Co. (NASDAQ:UTHR) CEO Martine A. Rothblatt Sells 3,600 Shares

United Therapeutics Co. (NASDAQ:UTHR) CEO Martine A. Rothblatt sold 3,600 shares of the business’s stock in a transaction that occurred on Friday, April 26th. The shares were sold at an average price of $235.20, for a total value of $846,720.00. Following the transaction, the chief executive officer now owns 130 shares of the company’s stock, valued at approximately $30,576. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.

United Therapeutics Price Performance

Shares of UTHR traded up $4.41 during midday trading on Monday, reaching $238.26. The stock had a trading volume of 496,599 shares, compared to its average volume of 439,061. The company has a debt-to-equity ratio of 0.05, a current ratio of 4.41 and a quick ratio of 4.28. The company has a market capitalization of $11.21 billion, a P/E ratio of 12.14 and a beta of 0.52. The firm’s 50 day moving average price is $233.74 and its 200-day moving average price is $228.76. United Therapeutics Co. has a 52 week low of $204.44 and a 52 week high of $261.54.

United Therapeutics (NASDAQ:UTHR) last issued its earnings results on Wednesday, February 21st. The biotechnology company reported $4.36 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $4.28 by $0.08. The business had revenue of $614.70 million for the quarter, compared to analysts’ expectations of $575.01 million. United Therapeutics had a return on equity of 17.72% and a net margin of 42.31%. The company’s quarterly revenue was up 25.1% on a year-over-year basis. During the same period in the previous year, the firm posted $2.67 EPS. On average, analysts forecast that United Therapeutics Co. will post 23.45 earnings per share for the current fiscal year.

Hedge Funds Weigh In On United Therapeutics

A number of hedge funds have recently modified their holdings of the stock. Norges Bank purchased a new position in shares of United Therapeutics during the fourth quarter valued at $100,519,000. Avidity Partners Management LP purchased a new position in shares of United Therapeutics during the fourth quarter valued at $52,158,000. Comerica Bank grew its holdings in shares of United Therapeutics by 2,697.2% during the third quarter. Comerica Bank now owns 156,587 shares of the biotechnology company’s stock valued at $35,368,000 after buying an additional 150,989 shares in the last quarter. Victory Capital Management Inc. grew its holdings in shares of United Therapeutics by 309.7% during the fourth quarter. Victory Capital Management Inc. now owns 134,162 shares of the biotechnology company’s stock valued at $29,501,000 after buying an additional 101,419 shares in the last quarter. Finally, TD Asset Management Inc grew its holdings in shares of United Therapeutics by 1,066.4% during the fourth quarter. TD Asset Management Inc now owns 82,951 shares of the biotechnology company’s stock valued at $18,240,000 after buying an additional 75,839 shares in the last quarter. 94.08% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several analysts have weighed in on UTHR shares. StockNews.com downgraded United Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Thursday, April 11th. HC Wainwright reaffirmed a “buy” rating and set a $300.00 target price on shares of United Therapeutics in a research note on Thursday, February 22nd. Leerink Partnrs reaffirmed an “outperform” rating on shares of United Therapeutics in a research note on Monday, February 5th. The Goldman Sachs Group raised United Therapeutics from a “sell” rating to a “neutral” rating and lifted their target price for the company from $213.00 to $215.00 in a research note on Monday, February 12th. Finally, Wedbush reaffirmed an “outperform” rating and set a $308.00 target price on shares of United Therapeutics in a research note on Thursday, February 22nd. One equities research analyst has rated the stock with a hold rating and nine have issued a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $294.25.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.